Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Tappenden

Showing results (1-10 of 81) with videos related to

Pageof 9
Sort By:
Current Opinion in Pulmonary Medicine|September 16, 2014
Dry powder inhalers in cystic fibrosis: same old drugs but different benefits?Lesley Uttley, Paul Tappenden
Pharmacoeconomics|July 17, 2014
Avoiding and identifying errors and other threats to the credibility of health economic modelsPaul Tappenden, James B Chilcott
Pharmacoeconomics|October 24, 2019
Improving Transparency in Decision Models: Current Issues and Potential SolutionsPaul Tappenden, J Jaime Caro
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Reviewing the evidence to inform the population of cost-effectiveness models within health technology assessmentsEva Kaltenthaler, Paul Tappenden, Suzy Paisley
Pharmacoeconomics|March 25, 2017
An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic FibrosisPaul Tappenden, Susannah Sadler, Martin Wildman
Pharmacoeconomics|July 28, 2017
Replicating Health Economic Models: Firm Foundations or a House of Cards?Inigo Bermejo, Paul Tappenden, Ji-Hee Youn
Pharmacoeconomics|September 29, 2017
Response to 'Comment on "Replicating Health Economic Models: Firm Foundations or a House of Cards?"'Inigo Bermejo, Paul Tappenden, Ji-Hee Youn
Pharmacoeconomics|May 19, 2021
Estimation of Transition Probabilities for State-Transition Models: A Review of NICE AppraisalsTushar Srivastava, Nicholas R Latimer, Paul Tappenden
Medical Decision Making : an International Journal of the Society for Medical Decision Making|November 9, 2024
Assessing Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Simulation StudyAbualbishr Alshreef, Nicholas Latimer, Paul Tappenden, et al.
British Journal of Cancer|September 11, 2020
A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancerKaty Cooper, Paul Tappenden, Anna Cantrell, et al.
Pageof 9

Showing results (1-10 of 81) with videos related to

Sort By:
Pageof 9
Current Opinion in Pulmonary Medicine|September 16, 2014
Dry powder inhalers in cystic fibrosis: same old drugs but different benefits?Lesley Uttley, Paul Tappenden
Pharmacoeconomics|July 17, 2014
Avoiding and identifying errors and other threats to the credibility of health economic modelsPaul Tappenden, James B Chilcott
Pharmacoeconomics|October 24, 2019
Improving Transparency in Decision Models: Current Issues and Potential SolutionsPaul Tappenden, J Jaime Caro
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Reviewing the evidence to inform the population of cost-effectiveness models within health technology assessmentsEva Kaltenthaler, Paul Tappenden, Suzy Paisley
Pharmacoeconomics|March 25, 2017
An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic FibrosisPaul Tappenden, Susannah Sadler, Martin Wildman
Pharmacoeconomics|July 28, 2017
Replicating Health Economic Models: Firm Foundations or a House of Cards?Inigo Bermejo, Paul Tappenden, Ji-Hee Youn
Pharmacoeconomics|September 29, 2017
Response to 'Comment on "Replicating Health Economic Models: Firm Foundations or a House of Cards?"'Inigo Bermejo, Paul Tappenden, Ji-Hee Youn
Pharmacoeconomics|May 19, 2021
Estimation of Transition Probabilities for State-Transition Models: A Review of NICE AppraisalsTushar Srivastava, Nicholas R Latimer, Paul Tappenden
Medical Decision Making : an International Journal of the Society for Medical Decision Making|November 9, 2024
Assessing Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Simulation StudyAbualbishr Alshreef, Nicholas Latimer, Paul Tappenden, et al.
British Journal of Cancer|September 11, 2020
A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancerKaty Cooper, Paul Tappenden, Anna Cantrell, et al.
Pageof 9